Sarepta Therapeuticsの空売り状況は、投資家がSarepta Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Sarepta Therapeutics (NASDAQ:SRPT) 株価情報, 空売り情報

Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics Inc

On Monday, Arrowhead Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company&#8217;s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44216024/arrowhead-pharmaceuticals-announces-topline-results-from-part-2-of-phase-12-study-of-aro-c3-in-pat" rel="noreferrer noopener">complement-mediated diseases</a>.
ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential treatment for various complement-mediated renal diseases.&nbsp;
The dysregulated activity of the complement system can contribute to tissue injury and the progression of the disease. By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal diseases by modulating the activation of the complement cascade.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44223155/veren-soars-on-whitecap-merger-deal-details" rel="noreferrer noopener">Veren Soars On Whitecap Merger Deal: Details</a>
The company plans to present additional results at a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44216024/arrowhead-pharmaceuticals-announces-topline-results-from-part-2-of-phase-12-study-of-aro-c3-in-pat" rel="noreferrer noopener">medical meeting in 2025</a>.
Select Phase 1/2 Study Results
<ul>
<li>Pharmacodynamic effects: Maximum mean reduction in C3 of 89% and mean sustained reduction of greater than 87% from baseline through week 24.</li>
<li>Maximum mean reduction in serum AH50 (alternative pathway hemolytic assay) of 85% and mean sustained reduction greater than 76%.</li>
<li>Maximum mean reduction in Wieslab AP (alternative pathway) of 100% and mean sustained reduction greater than 89%.</li>
<li>Duration of effect supportive of once every three months or less frequent subcutaneous dosing in later-stage studies</li>
<li>Effects on proteinuria (too much protein in the urine): The mean reduction in spot UPCR was 41%, and the maximum individual reduction was 89%.</li>
</ul>
In January, the U.S. Food and Drug Administration accepted Arrowhead Pharmaceuticals&#8217; New Drug Application for investigational plozasiran for familial chylomicronemia syndrome, a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43067733/arrowhead-pharmaceuticals-announces-acceptance-of-new-drug-application-by-u-s-fda-of-plozasiran-fo" rel="noreferrer noopener">advisory committee meeting</a>.
In February, Arrowhead Pharmaceuticals closed a global licensing and collaboration agreement with Sarepta Therapeutics Inc. Arrowhead receives a $500 million upfront payment and $325 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43591315/arrowhead-pharmaceuticals-announces-closing-of-global-license-and-collaboration-agreement-with-sar" rel="noreferrer noopener">through Sarepta stock</a>.
Price Action: ARWR stock is down 8.72% at $15.49 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44220746/pfizers-covid-19-shot-partner-biontech-reports-q4-profit-but-2025-guidance-falls-short-on-expectations" target="_blank" rel="noreferrer noopener">Pfizer&#8217;s COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations</a></li>
</ul>
Photo via Shutterstock.

Biotech

Equities

News

Health Care

Movers

General

ARWR

SRPT

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

Scotiabank analyst Louise Chen initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sector Perform rating and announces Price Target of $105.

Price Target

Initiation

Analyst Ratings

Scotiabank Initiates Coverage On Sarepta Therapeutics with Sector Perform Rating, Announces Price Target of $105

Offerings

Sarepta Therapeutics Files For Mixed Shelf; Size Not Disclosed

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $165 to $161.

RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $161

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and maintains $202 price target.

Reiteration

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target

In the last three months, 8 analysts have published ratings on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $106.75, a high estimate of $202.00, and a low estimate of $75.00. A 0.59% drop is evident in the current average compared to the previous average price target of $107.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1740657652_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Sarepta Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Sell</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Sarepta Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Sarepta Therapeutics</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
<h3>Unraveling the Financial Story of Sarepta Therapeutics</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Sarepta Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 40.79%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sarepta Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 7.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's ROE excels beyond industry benchmarks, reaching 2.93%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.96%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.14, Sarepta Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Have This To Say About Sarepta Therapeutics

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell and maintains $75 price target.

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target

WIIM

Sarepta Therapeutics shares are trading lower. The company reported Q4 financial results.

Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) reported quarterly earnings of $1.90 per share which met the analyst consensus estimate. This is a 131.71 percent increase over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $658.412 million which beat the analyst consensus estimate of $627.582 million by 4.91 percent. This is a 65.94 percent increase over sales of $396.781 million the same period last year.

Earnings

Earnings Beats

Sarepta Therapeutics Q4 2024 Adj. EPS $1.90, Inline, Sales $658.412M Beat $627.582M Estimate

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$48.00</td>
<td>$81.9K</td>
<td>541</td>
<td align="right">474</td>
</tr>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$380.00</td>
<td>$74.5K</td>
<td>42</td>
<td align="right">88</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$295.00</td>
<td>$34.6K</td>
<td>148</td>
<td align="right">31</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$26.3K</td>
<td>2.6K</td>
<td align="right">26</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$110.00</td>
<td>$25.4K</td>
<td>86</td>
<td align="right">25</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$300.00</td>
<td>$91.7K</td>
<td>3</td>
<td align="right">15</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$960.00</td>
<td>$120.4K</td>
<td>79</td>
<td align="right">10</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$480.00</td>
<td>$27.2K</td>
<td>1.1K</td>
<td align="right">9</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$280.00</td>
<td>$32.2K</td>
<td>2</td>
<td align="right">6</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$590.00</td>
<td>$26.2K</td>
<td>7</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with neutral sentiment. It expires in 50 day(s) on April 17, 2025. Parties traded 200 contract(s) at a $48.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $81.9K, with a price of $410.0 per contract. There were 541 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• For MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we notice a call option sweep that happens to be bearish, expiring in 50 day(s) on April 17, 2025. This event was a transfer of 25 contract(s) at a $380.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $74.5K, with a price of $2970.0 per contract. There were 42 open contracts at this strike prior to today, and today 88 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be neutral, expiring in 2 day(s) on February 28, 2025. This event was a transfer of 25 contract(s) at a $295.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $1387.0 per contract. There were 148 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be neutral, expiring in 324 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $1315.0 per contract. There were 2612 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with neutral sentiment. It expires in 79 day(s) on May 16, 2025. Parties traded 25 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $1020.0 per contract. There were 86 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with neutral sentiment. It expires in 2 day(s) on February 28, 2025. Parties traded 5 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $91.7K, with a price of $18346.0 per contract. There were 3 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bearish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $960.00 strike. The total cost received by the writing party (or parties) was $120.4K, with a price of $12040.0 per contract. There were 79 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 5 contract(s) at a $480.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $5455.0 per contract. There were 1141 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bearish sentiment. It expires in 387 day(s) on March 20, 2026. Parties traded 6 contract(s) at a $280.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $5383.0 per contract. There were 2 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bullish, expiring in 688 day(s) on January 15, 2027. This event was a transfer of 5 contract(s) at a $590.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $5258.0 per contract. There were 7 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MDGL

TGTX

VRTX

10 Health Care Stocks Whale Activity In Today's Session

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RXRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.00</td>
<td>$26.6K</td>
<td>2.5K</td>
<td>4.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$95.5K</td>
<td>1.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$200.00</td>
<td>$192.0K</td>
<td>55</td>
<td>286</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$153.7K</td>
<td>609</td>
<td>250</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$85.00</td>
<td>$26.1K</td>
<td>2.6K</td>
<td>216</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$50.00</td>
<td>$56.0K</td>
<td>1.3K</td>
<td>201</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$60.00</td>
<td>$40.1K</td>
<td>13.3K</td>
<td>156</td>
</tr>
<tr>
<td>ARWR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$27.4K</td>
<td>385</td>
<td>110</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$77.50</td>
<td>$35.0K</td>
<td>176</td>
<td>46</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$100.00</td>
<td>$35.6K</td>
<td>602</td>
<td>30</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we notice a put option sweep that happens to be bullish, expiring in 35 day(s) on March 21, 2025. This event was a transfer of 533 contract(s) at a $8.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $26.6K, with a price of $50.0 per contract. There were 2587 open contracts at this strike prior to today, and today 4649 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option trade that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $95.5K, with a price of $191.0 per contract. There were 1849 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we notice a call option sweep that happens to be bearish, expiring in 308 day(s) on December 19, 2025. This event was a transfer of 40 contract(s) at a $200.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $192.0K, with a price of $4800.0 per contract. There were 55 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we observe a put option trade with bullish sentiment. It expires in 336 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $153.7K, with a price of $615.0 per contract. There were 609 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option trade that happens to be bullish, expiring in 154 day(s) on July 18, 2025. This event was a transfer of 39 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $670.0 per contract. There were 2690 open contracts at this strike prior to today, and today 216 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option trade that happens to be bearish, expiring in 7 day(s) on February 21, 2025. This event was a transfer of 50 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $1120.0 per contract. There were 1300 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 35 day(s) on March 21, 2025. Parties traded 59 contract(s) at a $60.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $40.1K, with a price of $680.0 per contract. There were 13329 open contracts at this strike prior to today, and today 156 contract(s) were bought and sold. 
• For ARWR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>), we notice a call option sweep that happens to be bullish, expiring in 126 day(s) on June 20, 2025. This event was a transfer of 100 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $276.0 per contract. There were 385 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option trade with neutral sentiment. It expires in 7 day(s) on February 21, 2025. Parties traded 35 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1000.0 per contract. There were 176 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we notice a put option sweep that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 30 contract(s) at a $100.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $35.6K, with a price of $1177.0 per contract. There were 602 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXAS

MRNA

RXRX

SWTX

10 Health Care Stocks With Whale Alerts In Today's Session

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell and maintains $75 price target.

On Monday, Sarepta Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) released topline results from Part 2 of EMBARK (Study SRP-9001-301) Phase 3 clinical study of Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with <a target="_blank" href="https://www.benzinga.com/quote/SRPT" rel="noreferrer noopener">Duchenne muscular dystrophy</a>.
Crossover-treated patients who received a placebo in Part 1, crossed over at 52 weeks and were treated with Elevidys in Part 2 improved 2.34 points from baseline compared to matched external controls on the North Star Ambulatory Assessment (NSAA) 52 weeks after treatment. NSAA measures functional motor abilities in <a href="https://www.benzinga.com/pressreleases/25/01/b43220537/sarepta-therapeutics-announces-results-from-part-2-of-the-embark-study-demonstrating-sustained-ben" target="_blank" rel="noreferrer noopener">children with Duchenne</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42883730/solid-biosciences-outpaces-competitors-in-duchenne-gene-therapy-development" rel="noreferrer noopener">Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development</a>
Despite being one year older (average age 7.18 years) than those treated in Part 1 (average age 5.98 years), crossover-treated patients showed clinically meaningful and statistically significant functional benefit for NSAA, Time to Rise (TTR) and 10-meter walk/run (10MWR) function tests compared with a pre-specified, propensity-weighted external control group (EC).
Individuals treated in part one of EMBARK (n=63) showed clinically meaningful and statistically significant improvements on the NSAA sustained two years after treatment with Elevidys. Functional motor improvements include:
<ul>
<li>+2.88 points (improvement) on NSAA.</li>
<li>-2.06 seconds (improvement) on Time to Rise.</li>
<li>-1.36 seconds (improvement) on 10MWR.</li>
</ul>
Muscle biopsies from a subset of patients taken 64 weeks after dosing in part one showed consistent and sustained expression of micro-dystrophin. Muscle pathology on MRI continues to show minimal progression in underlying muscle pathology and remains highly consistent with the functional benefits shown.
No new safety signals were observed.
As part of a collaboration agreement signed in 2019, Sarepta is working with Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>). Sarepta is responsible for regulatory approval and commercializing Elevidys in the U.S. and manufacturing.
Roche is responsible for regulatory approvals and bringing Elevidys to patients across the rest of the world.
Price Action: SRPT stock closed at $116.46 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43200965/goldman-sachs-stays-on-the-sidelines-on-exxon-mobil-heres-why" target="_blank" rel="noreferrer noopener">Goldman Sachs Stays On The Sidelines On Exxon Mobil &#8211; Here&#8217;s Why</a></li>
</ul>

RHHBY

Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years

– Treatment with ELEVIDYS corresponded with increases on the North Star Ambulatory Assessment (NSAA) at one year in crossover patients, while the study remained blinded
– MRI results at two years in patients treated in Part 1 show minimal muscle pathology progression, aligning closely with observed functional benefits
– Crossover-treated patients show statistically significant benefits of ELEVIDYS treatment on NSAA, Time to Rise (TTR), and 10-meter walk/run (10MWR), when compared to a pre-specified, well-matched external control (EC)
– Part 1-treated patients show sustained expression at week 64, and functional improvements on NSAA, TTR and 10MWR were sustained two years after treatment and show a widening divergence compared to EC
– Safety remained consistent with the profile of ELEVIDYS already established across a broad Duchenne population
– Investor webcast to be held today at 8:30 a.m. ET

Sarepta's EMBARK Study Part 2 Results: ELEVIDYS Gene Therapy Shows Sustained Functional Gains And Disease Stabilization In Duchenne Muscular Dystrophy

Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of $205.00, and a low estimate of $75.00. Observing a downward trend, the current average is 4.38% lower than the prior average price target of $158.58. 
<img src="https://www.benzinga.com/files/images/story/2025/1736978422_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Sarepta Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Sell</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$202.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Sell</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$167.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sarepta Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sarepta Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>All You Need to Know About Sarepta Therapeutics</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
<h3>Sarepta Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sarepta Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 40.79%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sarepta Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 2.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sarepta Therapeutics's ROA excels beyond industry benchmarks, reaching 0.96%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.14.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 14 Analyst Ratings Have To Say About Sarepta Therapeutics

– Preliminary total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for full-year 2024, exceeding full-year guidance by over $100 million
– Preliminary ELEVIDYS net product revenue totaled $384.2 million for the fourth quarter, exceeding guidance by over $60 million, and $820.8 million for full-year 2024
– Preliminary RNA-based PMO net product revenue for the fourth quarter and full-year of 2024 totaled $254.0 million and $967.2 million, respectively
– Preliminary year-end 2024 cash, cash equivalents, restricted cash and investments balance of approximately $1.5 billion
– Reiterates 2025 full-year total net product revenue guidance of $2.9 to $3.1 billion
Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), the leader in precision genetic medicine for rare diseases, today reported preliminary&#x2A; fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

Guidance

Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B

Press Releases

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Small Cap

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

Comments

Sarepta Therapeutics

空売り

Sarepta Therapeutics (NASDAQ:SRPT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル